Ann: Oncosil breakthrough device receives CE Marking approval, page-150

I can imagine it must be confusing when more than one person on here has a good grasp of the subject matter.

for those investors interested in other things happening in this disease landscape , worth spending a few mins checking out what Novocure is doing with TT fields device. They’re already approved for glioblastoma in US. Advanced development programme now in locally adv. pc and quite some striking similarity to OSL’s programme . They also completed a small single arm feasibility trial published in Pancreatology (Rivera et al) in Jan 2019, combining TTF with gem or gem + abr though allowed stages 3&4 pc. Strong PFS results >10 months with device plus best chemo. . They’re now onto phase 3 pivotal which looks identical in design to what OSL has previously informed market they’d be doing. Novocure’s is a 556 patient RCT in L.A. pancreatic cancer , TTF plus gemcitabine-abraxane vs gem- abraxane alone as control. (Panova-3 trial).